472 related articles for article (PubMed ID: 30911883)
1. Preliminary clinical assessment of dynamic
Shinya T; Otomi Y; Kubo M; Kinoshita M; Takechi K; Uyama N; Yamanaka M; Terazawa K; Toba H; Bando Y; Otsuka H; Harada M
Ann Nucl Med; 2019 Jun; 33(6):414-423. PubMed ID: 30911883
[TBL] [Abstract][Full Text] [Related]
2. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
[TBL] [Abstract][Full Text] [Related]
3. Semiquantitative assessment of fluorodeoxyglucose uptake in primary tumours on dynamic PET/computed tomography for lymph node metastasis evaluation in patients with lung cancer: a prospective study.
Yamanaka M; Shinya T; Otomi Y; Kubo M; Arai Y; Toba H; Bando Y; Otsuka H; Harada M
Nucl Med Commun; 2020 Nov; 41(11):1189-1198. PubMed ID: 32796454
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
5. Dual-time point
Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Dual-Timepoint
Collarino A; Garganese G; Valdés Olmos RA; Stefanelli A; Perotti G; Mirk P; Fragomeni SM; Ieria FP; Scambia G; Giordano A; Rufini V
J Nucl Med; 2017 Dec; 58(12):1913-1918. PubMed ID: 28546331
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
9. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Zhai X; Guo Y; Qian X
Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
11. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
12. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
[TBL] [Abstract][Full Text] [Related]
13. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer.
Shigemoto Y; Suga K; Matsunaga N
Ann Nucl Med; 2016 May; 30(4):287-97. PubMed ID: 27007128
[TBL] [Abstract][Full Text] [Related]
14. Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.
Rogasch JM; Steffen IG; Riedel S; Apostolova I; Wertzel H; Achenbach HJ; Steinkrüger FL; Kalinski T; Schultz M; Schreiber J; Amthauer H; Furth C
Eur Radiol; 2016 Aug; 26(8):2808-18. PubMed ID: 26560731
[TBL] [Abstract][Full Text] [Related]
15. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
[TBL] [Abstract][Full Text] [Related]
16. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A
Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919
[TBL] [Abstract][Full Text] [Related]
17. [
Li Y; Zhang Y; Guo Z; Hou P; Lv J; Ke M; Liu S; Li S; Yin W; He J; Wang X
Cancer Imaging; 2024 Jun; 24(1):68. PubMed ID: 38831354
[TBL] [Abstract][Full Text] [Related]
18. Improving diagnostic performance of
Yang DD; Mirvis E; Goldring J; Patel ARC; Wagner T
Clin Radiol; 2019 Oct; 74(10):818.e17-818.e23. PubMed ID: 31420186
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
Ohno Y; Fujisawa Y; Sugihara N; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2017 Nov; 209(5):W253-W262. PubMed ID: 28929810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
